Fresenius Kabi, the generics unit of German healthcare giant Fresenius, announced on 1 August 2022 that the US Food and Drug Administration (FDA) had accepted the application for their proposed tocilizumab biosimilar (MSB11456).
FDA accepts application for tocilizumab biosimilar
Biosimilars/News | Posted 02/09/2022 0 Post your comment
MSB11456 is a proposed biosimilar of Roche’s Actemra/RoActemra (tocilizumab), which had worldwide sales of CHF 3.6 billion (US$3.7 billion) in 2021 .
Tocilizumab is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). It is an immunosuppressive drug used mainly for the treatment of rheumatoid arthritis and systemic juvenile idiopathic arthritis, a severe form of arthritis in children. In Japan, tocilizumab is also approved for the treatment of Castleman’s disease, a rare benign tumour of B cells .
The application is supported by analytical similarity and comprehensive clinical data. These are used to demonstrate similar pharmacokinetic, efficacy, safety, tolerability, and immunogenicity to the reference product, with and without switch from tocilizumab patients to MSB11456. The application includes presentations for both subcutaneous (pre-filled syringe and autoinjector) and intravenous administrations, which, according to Fresenius Kabi is ‘designed to provide a comprehensive offering for patients treated with tocilizumab’.
If approved, MSB11456 would be the first tocilizumab biosimilar to be approved in the US and would also mark Fresenius Kabi’s first biosimilar approval in the country. To date, there are no other tocilizumab biosimilars approved in the US or in Europe [2, 3]. The company has two other biosimilars approved in Europe; Idacio (adalimumab) and Stimufend (pegfilgrastim) .
Readers interested to learn more about tocilizumab biosimilars are invited to visit www.gabi-journal.net to view the following manuscript published in GaBI Journal:
GaBI Journal is indexed in Embase, Scopus, Emerging Sources Citation Index and more.
Readers interested in contributing a research or perspective paper to GaBI Journal – an independent, peer reviewed academic journal – please send us your submission here.
Submit a manuscript to GaBI Journal
LATIN AMERICAN FORUM
The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.
View the latest headline article: Acceso a biosimilares para tratamientos contra el cáncer en América Latina
Browse the news in the Latin American Forum!
Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.
Ver el último artículo de cabecera: Acceso a biosimilares para tratamientos contra el cáncer en América Latina
!Explore las noticias en el Foro Latinoamericano!
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of tocilizumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Sep 2]. Available from: www.gabionline.net/biosimilars/general/Biosimilars-of-tocilizumab
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in the US [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Sep 2]. Available from: www.gabionline.net/biosimilars/general/biosimilars-approved-in-the-us
3. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Europe [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Sep 2]. Available from: www.gabionline.net/biosimilars/general/biosimilars-approved-in-europe
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.
Source: Fresenius Kabi